Europe’s universal PFAS restriction would phase out more than 10,000 “forever chemicals” under REACH, including the fluoropolymers that line pharma reactors, pipework and single-use systems. Both of ECHA’s scientific committees now back the restriction, and the European Commission drafts the legal text next. Few medicines contain PFAS, but almost every EU production line depends on it.
EU PFAS restriction: latest updates
- Nov 19, 2026: ECHA’s Committee for Socio-Economic Analysis (SEAC) adopted its final opinion. It backs an EU-wide restriction with a phased ban and time-limited derogations of 5 to 12 years for critical uses with no viable alternative.
- Jun 15, 2026: Environment Commissioner Jessika Roswall raised splitting the restriction between consumer and industrial uses at a high-level dialogue with industry.
- Mar 26, 2026: ECHA published SEAC’s draft opinion. SEAC found the proposed time-unlimited derogation for active substances in medicines “has not been justified.”
- Mar 2, 2026: ECHA’s Risk Assessment Committee (RAC) adopted its final opinion, confirming PFAS hazards and concluding that existing EU measures are insufficient.
EU PFAS restriction at a glance
| Region | European Union and EEA |
| Instrument | REACH Annex XVII restriction covering PFAS as a group |
| Proposed by | Germany, the Netherlands, Denmark, Norway and Sweden (January 2023) |
| Scope | More than 10,000 PFAS, including fluoropolymers such as PTFE, PVDF and FEP |
| Legal status | Proposed. ECHA committee opinions complete; Commission proposal pending |
| Key date | Commission proposal and REACH Committee vote, expected 2027 |
| Transition | Default ban 18 months after entry into force; derogations of 6.5 or 13.5 years from entry into force |
| Most exposed | EU API, biologics and fill-finish sites using fluoropolymer equipment; equipment and single-use suppliers |
| Official source | ECHA |
| PharmaSource Score | 216 (rank 10) Impact 6, Reach 6, Likelihood 6 Download the PharmaSource Regulatory Radar |
What the EU PFAS restriction is
PFAS are synthetic chemicals built on carbon-fluorine bonds, among the strongest in chemistry. The bond lets PFAS resist heat, acids and solvents, and keeps them in water and soil for decades. In January 2023, five national authorities proposed restricting the whole family at once under REACH, the broadest chemical restriction the EU has attempted.
The proposal works through six levers:
- Group approach: PFAS are restricted as a class under the OECD definition.
- Default ban: Manufacture, use and placing on the market end 18 months after entry into force, unless a derogation applies.
- Time-limited derogations: Uses without alternatives run for 6.5 or 13.5 years from entry into force. The 2025 update raised the number of derogated uses from 26 to 74.
- Fluoropolymers in scope: Both committees rejected industry requests to exclude fluoropolymers, citing emissions across their life cycle.
- Conditions on derogated uses: Companies report volumes to ECHA, and sites using derogated fluoropolymers keep site-specific PFAS management plans.
- Imports covered: The restriction applies to imported goods as well as EU manufacture.
Medicines got special treatment in the original dossier: a time-unlimited derogation for active substances in human and veterinary medicines. That derogation protects very little of the industry. An EFPIA survey found only 139 of 1,922 affected active substances, about 7%, contain a PFAS moiety. The rest are caught because fluoropolymers sit in the equipment, packaging or devices used to make and deliver them.
Where the EU PFAS restriction stands
- January 2023: Five national authorities submit the restriction to ECHA.
- March to September 2023: First public consultation draws more than 5,600 comments.
- August 2025: An updated proposal adds eight sectors, including sealing, machinery and other medical applications. The committees decide not to evaluate those eight sectors separately, to finish on time.
- March 2026: RAC adopts its final opinion. SEAC agrees a draft and opens a 60-day consultation, which closes May 25 with 3,511 comments.
- November 19, 2026: SEAC adopts its final opinion, concluding ECHA’s scientific evaluation.
According to Agence Europe, the final opinion rejects a blanket ban within 18 months. It backs an 18-month ban for consumer uses and sectors with alternatives, and 5 to 12 years for critical uses such as semiconductors, medical devices, aviation and spare parts for installed machinery. Until ECHA publishes the full text, the March draft is the best guide to how medicines fare.
That draft was tough on pharma. It found no case for derogations for excipients in most human medicines, according to Enhesa. Medicine blisters would get 6.5 years, while stoppers, syringes, inhalers and injection devices would get 13.5 years, Covington reports. Seals and machinery parts fall in the eight sectors the committees left unassessed, so SEAC recommended an interim, time-limited derogation for them until a full assessment is done.
What the EU PFAS restriction means for manufacturing and outsourcing
Pharma plants use fluoropolymers because they resist solvents and acids, survive steam sterilization and shed very little into the product. Brussels policy advisor Neha Dave told the PharmaSource Podcast that “this issue of banning PFAS is going straight to the core of the industry.” The exposure differs by type of site:
- API and small molecule CDMOs: PTFE-lined reactors, pipework, valve seats, gaskets and seals run through most synthesis plants. Replacing them means requalification and, in some cases, regulatory variations. EFPIA also warns that fluorinated building blocks, reagents and intermediates sit outside the active substance derogation.
- Biologics and cell and gene therapy CDMOs: Single-use bags, tubing, connectors and PVDF or PTFE filter membranes carry fluoropolymers. The Bio-Process Systems Alliance puts dependence at 94% to virtually all biologics, and EFPIA members estimate a full replacement program could take around 20 years.
- Fill-finish and drug-device sites: Stoppers, syringe coatings, inhaler parts and blister films all carry derogation clocks. Each substitution needs stability, extractables and leachables data, then a change to the marketing authorization.
- Equipment and single-use suppliers: Suppliers carry the substitution work, and CDMOs need their data before qualifying alternatives.
- Sites outside the EU: The restriction governs PFAS used and placed on the EU market, so plants in Asia and the US keep their current equipment. Medicines for Europe has warned that green rules could push production offshore, the opposite of what the Critical Medicines Act wants.
- Early-stage biotechs: Regulatory consultant Agneta Larhed of RegSmart Life Science told CDMO Live that early-stage companies “are not very well aware of these issues during early development.”
For outsourcing leaders, the practical step is to ask each EU CDMO for a fluoropolymer inventory by line, the derogation each component relies on and a dated replacement and requalification plan.
Why supporters back the EU PFAS restriction
“PFAS pollution is an immense challenge that needs to be addressed collectively.”
Jessika Roswall, EU Environment Commissioner, quoted by Smart Water Magazine
- Persistence and health: PFAS and their breakdown products accumulate in water and soil. SEAC’s draft linked exposure to effects on the liver, cholesterol, birth weight, immune function and vaccine response.
- Existing rules fall short: Both committees concluded that current EU measures fail to control PFAS emissions.
- Fluoropolymer life cycle: RAC kept fluoropolymers in scope because their production and disposal can release smaller, mobile PFAS.
- One rulebook: A single EU restriction replaces a patchwork of national bans, which Roswall has said the single market needs.
- Restrictions spur innovation: Elisabeth Stampa of Medicines for Europe told CDMO Live that with each restriction “the industry gets more creative on how to overcome it,” citing flow and enzymatic chemistry.
Criticisms of the EU PFAS restriction
“It would have a tremendous impact in the industry.”
Elisabeth Stampa, Vice President, Medicines for Europe, speaking at CDMO Live
- Medicine supply: EFPIA warns that without a time-unlimited derogation, products could be withdrawn as early as 18 months after entry into force, and that more than 650 medicines on the WHO Essential Medicines List are at risk. Medicines, it says, “cannot be substituted on a one-to-one basis.”
- Arbitrary deadlines: SEAC itself said the 5- and 12-year periods were chosen “rather arbitrarily.” Industry estimates for replacing fluoropolymers in biologics plants run to two decades.
- Fluoropolymers are different: Industry argues that PTFE and PVDF are inert, high-molecular-weight materials the OECD treats as polymers of low concern, unlike PFOA or PFOS.
- Unassessed sectors: Seals and machinery, where most pharma equipment sits, got no sector-specific evaluation and rely on interim derogations.
- Compliance cost: SEAC warned that monitoring, management plans and reporting would burden SMEs, and its draft judged site-specific management plans costly and hard to enforce.
- Supply chain blind spots: Dave notes PFAS can arrive in raw materials, “which of course CDMOs have no control over.”
What’s next for the EU PFAS restriction
- Final text: ECHA publishes SEAC’s full opinion in the coming weeks. Read the medicine, packaging and equipment derogations first.
- Commission proposal and vote: The Commission drafts an amendment to REACH Annex XVII, possibly splitting consumer and industrial uses. Member states vote in the REACH Committee, then Parliament and Council have a scrutiny period. Law firms expect adoption in 2027.
- Application dates: If adopted in 2027, the default ban would apply around 2029, with derogated uses running to roughly 2033 or 2040.
- Our score: Impact 6, Reach 6, Likelihood 6, giving 216 and rank 10. A restriction is now very likely; the score holds at 6 because the scope of pharma derogations stays open until the Commission drafts.
Related articles
- How EU Sustainability Regulations Are Reshaping CDMO Manufacturing (Sep 7, 2026)
- Pharma Supply Chain Sustainability: How Sanofi, Sharp Services and My Green Lab Are Moving From Commitment to Execution (Oct 26, 2026)
- Critical Medicines Act: Europe’s Reshoring Regulation Explained (Nov 20, 2026)
- European Small Molecule Manufacturing at Critical Juncture as Green Rules Meet Market Reality (Jul 6, 2025)
- All coverage: EU PFAS Restriction